NASDAQ$CTKB
Cytek Biosciences Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Cytek Biosciences reported Q1 2025, revenue of $28.1M, net loss of $11.3M.
For Q1 2025, Cytek Biosciences reported revenue of $28.1M, a net loss of $11.3M. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Q1 2025 revenue $28.1M.
- Net loss $11.3M.
- Cytek Biosciences highlights liquidity, execution, and sector-specific risks in MD&A.
Headline financials
Revenue & EPS history
Cytek Biosciences · Revenue · Quarterly
$41.5M
Revenue by segment
Cytek Biosciences · $48M total across 2 segments · Q3 2023
- Product Revenue$38.4M+5.6%80.1%
- Service Revenue$9.56M+133.8%19.9%
Forward guidance
Life-sciences filers emphasize pipeline milestones, regulatory paths, and cash runway; product revenue is limited or emerging.
Tailwinds
- Pipeline progress and partnership optionality.
- Cash balances funding operations into upcoming catalysts.
- Commercial launches where approved.
Headwinds
- Trial failure or regulatory delay risk.
- Dilution from equity raises.
- Reimbursement and competitive pressure.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
-4.5%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+42.3%
Q3 2024
Best reaction
-23.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -18.4% | -17.2% | |
| Q4 2025 | +1.6% | +0.2% | -1.8% | |
| Q3 2025 | +2.6% | +21.5% | +27.6% | |
| Q1 2025 | -22.8% | -28.0% | -9.2% | |
| Q4 2024 | -6.7% | -7.1% | -16.8% | |
| Q3 2024 | +42.3% | +35.6% | +25.8% | |
| Q2 2024 | -12.7% | -10.5% | -6.7% | |
| Q1 2024 | -2.8% | -3.1% | -6.0% | |
| Q4 2023 | -13.0% | -8.2% | -12.9% | |
| Q3 2023 | +14.7% | +12.4% | +75.7% | |
| Q2 2023 | -2.0% | +2.4% | -25.1% | |
| Q1 2023 | -23.6% | -35.4% | -30.9% | |
| Q4 2022 | -10.0% | +0.7% | -15.5% | |
| Q3 2022 | -0.6% | +0.6% | -22.3% | |
| Q2 2022 | +1.0% | +1.9% | -4.0% | |
| Q1 2022 | +1.1% | +23.1% | +25.6% | |
| Q4 2021 | -1.9% | +1.3% | -26.5% | |
| Q3 2020 | +1.8% | -0.2% | -17.9% | |
| Q3 2021 | -0.9% | -4.4% | -19.0% | |
| Q2 2020 | -1.8% | +6.8% | -12.3% | |
| Q4 2020 | -1.8% | +6.8% | -12.3% | |
| Q2 2021 | +16.2% | +14.9% | +2.5% | |
| Q1 2021 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro